Lund, Sweden, 26 April 2019 – Xintela announces that the results of the company's glioblastoma study have now been published in the renowned international scientific journal Cancers. The publication demonstrates and discusses that Xintela's marker, integrin α10β1, regulates important functions of glioblastoma cells and is a potential new therapeutic target for the treatment of the highly aggressive brain tumor glioblastoma.
Glioblastoma is the most common and most aggressive brain tumor form in adults and there is a enormous need for new and better treatment strategies. Xintela has previously reported positive preclinical results in which an antibody directed against the company's marker integrin α10β1 and combined with a cell toxin (Antibody-Drug Conjugate, ADC) was able to kill glioblastoma cells, both in cell experiments and in an animal model. The article now published, demonstrates that integrin α10β1 is highly expressed on cells in glioblastoma tumors but not in normal brain tissue and that the integrin has an important functional role on the glioblastoma cells by regulating cell migration (movement), growth and survival. In addition, the results show that an ADC directed to integrin α10β1 can block the function of glioblastoma cells and lead to the killing of the glioblastoma cells both in cell experiments and in an animal model. These results demonstrate the potential of the Xintela marker integrin α10β1 as a novel therapeutic target for the treatment of glioblastoma.
“We are very pleased that our results have now been published in the renowned international scientific journal Cancers. This is very positive in our discussions with potential investors and partners in the development of a First-in-Class therapy for glioblastoma and other high-grade, aggressive tumors”, says Xintela's CEO Evy Lundgren-Åkerlund.
Integrin α10, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival by Matilda Munksgaard Thorén, Katarzyna Chmielarska Masoumi, Cecilia Krona, Xiaoli Huang, Soumi Kundu, Linnéa Schmidt, Karin Forsberg-Nilsson, Marcus Floyd Keep, Elisabet Englund, Sven Nelander, Bo Holmqvist and Evy Lundgren-Åkerlund. Cancers 2019, 11(4), 587.
To read the publication, visit: https://doi.org/10.3390/cancers11040587
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy [at] xintela.se
223 81 Lund